FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Friedman

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Procedures

Physiology

Intestinal Absorption

Disorders

Dental Plaque

Anatomy

Co-author Network

Publications

TOP 3
Gregory Burshtein; Michael Friedman; Sarit Greenberg; Amnon Hoffman
Transepithelial transport of a natural cholinesterase inhibitor, huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism.
Zakhar Nudelman; Michal Dranitzki Elhalal; Michael Friedman; Naama Keshet; Rakefet Czerninski
Levels of Sirolimus in saliva vs. blood--the rationale of topical oral use for oral malignancy.
Gilad Bachrach; Hamutal Altman; Paul E Kolenbrander; Natalia I Chalmers; Michal Gabai-Gutner; Amram Mor; Michael Friedman; Doron Steinberg
Resistance of Porphyromonas gingivalis ATCC 33277 to direct killing by antimicrobial peptides is protease independent.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Friedman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gregory Burshtein; Michael Friedman; Sarit Greenberg; Amnon Hoffman
Transepithelial transport of a natural cholinesterase inhibitor, huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism.
Planta medica 2013;79(3-4):259-65.
2013: Zakhar Nudelman; Michal Dranitzki Elhalal; Michael Friedman; Naama Keshet; Rakefet Czerninski
Levels of Sirolimus in saliva vs. blood--the rationale of topical oral use for oral malignancy.
Anticancer research 2013;33(2):661-3.
2008: Gilad Bachrach; Hamutal Altman; Paul E Kolenbrander; Natalia I Chalmers; Michal Gabai-Gutner; Amram Mor; Michael Friedman; Doron Steinberg
Resistance of Porphyromonas gingivalis ATCC 33277 to direct killing by antimicrobial peptides is protease independent.
Antimicrobial agents and chemotherapy 2008;52(2):638-42.
2006: Leonid Kagan; Noa Lapidot; Michel Afargan; David Kirmayer; Eytan Moor; Yael Mardor; Michael Friedman; Amnon Hoffman
Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans.
Journal of controlled release : official journal of the Controlled Release Society 2006;113(3):208-15.
2006: Gilad Bachrach; Michael Friedman; Gladis Gilinski; Doron Steinberg
Soluble sustained release gene delivery system.
Journal of biomedical materials research. Part A 2006;77(4):811-4.
2006: Doron Steinberg; Tamir Tal; Michael Friedman
Sustained-release delivery systems of triclosan for treatment of Streptococcus mutans biofilm.
Journal of biomedical materials research. Part B, Applied biomaterials 2006;77(2):282-6.
2005: Nicola Joseph Nasser; Adi Friedman; Michael Friedman; Eitan Moor; Rami Mosheiff
Guided bone regeneration in the treatment of segmental diaphyseal defects: a comparison between resorbable and non-resorbable membranes.
Injury 2005;36(12):1460-6.
2004: Amnon Hoffman; David Stepensky; Eran Lavy; Sara Eyal; Eytan A Klausner; Michael Friedman
Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.
International journal of pharmaceutics 2004;277(1-2):141-53.
2003: Eytan A Klausner; Eran Lavy; Miklos Barta; Eva Cserepes; Michael Friedman; Amnon Hoffman
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans.
Pharmaceutical research 2003;20(9):1466-73.
2003: Rami Mosheiff; Adi Friedman; Michael Friedman; Meir Liebergall
Quantification of guided regeneration of weight-bearing bones.
Orthopedics 2003;26(8):789-94.
2003: Eytan A Klausner; Eran Lavy; David Stepensky; Eva Cserepes; Miklos Barta; Michael Friedman; Amnon Hoffman
Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
Journal of clinical pharmacology 2003;43(7):711-20.
2003: Eytan A Klausner; Eran Lavy; Michael Friedman; Amnon Hoffman
Expandable gastroretentive dosage forms.
Journal of controlled release : official journal of the Controlled Release Society 2003;90(2):143-62.
2003: Nurit Beyth; Meir Redlich; Doron Harari; Michael Friedman; Doron Steinberg
Effect of sustained-release chlorhexidine varnish on Streptococcus mutans and Actinomyces viscosus in orthodontic patients.
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2003;123(3):345-8.
2003: Eytan A Klausner; Sara Eyal; Eran Lavy; Michael Friedman; Amnon Hoffman
Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs.
Journal of controlled release : official journal of the Controlled Release Society 2003;88(1):117-26.
2002: Doron Steinberg; Ramona Rozen; Eytan A Klausner; B Zachs; Michael Friedman
Formulation, development and characterization of sustained release varnishes containing amine and stannous fluorides.
Caries research 2002;36(6):411-6.
2002: Eytan A Klausner; Eran Lavy; David Stepensky; Michael Friedman; Amnon Hoffman
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs.
Pharmaceutical research 2002;19(10):1516-23.
2002: David Stepensky; Michael Friedman; Itamar Raz; Amnon Hoffman
Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(8):861-8.
2001: S Doron; Michael Friedman; M Falach; E Sadovnic; H Zvia
Antibacterial effect of parabens against planktonic and biofilm Streptococcus sobrinus.
International journal of antimicrobial agents 2001;18(6):575-8.
2001: David Stepensky; Michael Friedman; W Srour; Itamar Raz; Amnon Hoffman
Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation.
Journal of controlled release : official journal of the Controlled Release Society 2001;71(1):107-15.
2001: M Baluom; Michael Friedman; Abraham Rubinstein
Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems.
Journal of controlled release : official journal of the Controlled Release Society 2001;70(1-2):139-47.
2000: I Katzhendler; K Mäder; R Azoury; Michael Friedman
Investigating the structure and properties of hydrated hydroxypropyl methylcellulose and egg albumin matrices containing carbamazepine: EPR and NMR study.
Pharmaceutical research 2000;17(10):1299-308.
2000: M Baluom; Michael Friedman; P Assaf; Abdullah Haj-Yehia; Abraham Rubinstein
Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine.
Pharmaceutical research 2000;17(9):1071-6.
2000: Yossi Lomnicky; T Haimov; Myron H Luria; Michael Friedman; Amnon Hoffman
Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration.
Journal of pharmaceutical sciences 2000;89(8):1046-53.
2000: I Katzhendler; K Mäder; Michael Friedman
Structure and hydration properties of hydroxypropyl methylcellulose matrices containing naproxen and naproxen sodium.
International journal of pharmaceutics 2000;200(2):161-79.
2000: segev shani; Michael Friedman; Doron Steinberg
The anticariogenic effect of amine fluorides on Streptococcus sobrinus and glucosyltransferase in biofilms.
Caries research 2000;34(3):260-7.
2000: I Katzhendler; R Azoury; Michael Friedman
The effect of egg albumin on the crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets and in aqueous solutions.
Journal of controlled release : official journal of the Controlled Release Society 2000;65(3):331-43.
2000: I Katzhendler; K Mäder; Michael Friedman
Correlation between drug release kinetics from proteineous matrix and matrix structure: EPR and NMR study.
Journal of pharmaceutical sciences 2000;89(3):365-81.
1999: Amnon Hoffman; Yossi Lomnicky; Myron H Luria; Dalia Gilhar; Michael Friedman
Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.
Pharmaceutical research 1999;16(7):1093-7.
1999: Doron Steinberg; Zvia Hirschfeld; I Tayeb; S Ben-Yosef; A David; Michael Friedman
The effect of parabens in a mouthwash and incorporated into a sustained release varnish on salivary bacteria.
Journal of dentistry 1999;27(2):101-6.
1999: Doron Steinberg; Michael Friedman
Dental drug-delivery devices: local and sustained-release applications.
Critical reviews in therapeutic drug carrier systems 1999;16(5):425-59.
1998: Yossi Lomnicky; Michael Friedman; Myron H Luria; I Raz; Amnon Hoffman
The effect of the mode of administration on the hypolipidaemic activity of niacin: continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats.
The Journal of pharmacy and pharmacology 1998;50(11):1233-9.
1998: I Katzhendler; R Azoury; Michael Friedman
Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose.
Journal of controlled release : official journal of the Controlled Release Society 1998;54(1):69-85.
1998: Amnon Hoffman; Haim D Danenberg; I Katzhendler; R Shuval; Dalia Gilhar; Michael Friedman
Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form.
Journal of controlled release : official journal of the Controlled Release Society 1998;54(1):29-37.
1997: I Katzhendler; Amnon Hoffman; A Goldberger; Michael Friedman
Modeling of drug release from erodible tablets.
Journal of pharmaceutical sciences 1997;86(1):110-5.
1992: K Egbaria; Michael Friedman
Adsorption of fluorescein dyes on albumin microspheres.
Pharmaceutical research 1992;9(5):629-35.
1992: Daniel Ziskind; Doron Steinberg; Michael Friedman; J P Bernimoulin
Inhibition of plaque accumulation under periodontal dressing by sustained-release varnish of chlorhexidine.
Clinical preventive dentistry 1992;14(3):29-33.
1992: K Egbaria; Michael Friedman
Physicochemical properties of albumin microspheres determined by spectroscopic studies.
Journal of pharmaceutical sciences 1992;81(2):186-90.
1992: Ilana Heling; Doron Steinberg; S Kenig; I Gavrilovich; michael sela; Michael Friedman
Efficacy of a sustained-release device containing chlorhexidine and Ca(OH)2 in preventing secondary infection of dentinal tubules.
International endodontic journal 1992;25(1):20-4.
1992: Ilana Heling; M Sommer; Doron Steinberg; Michael Friedman; michael sela
Microbiological evaluation of the efficacy of chlorhexidine in a sustained-release device for dentine sterilization.
International endodontic journal 1992;25(1):15-9.
1991: Ayala Stabholz; Joseph Shapira; D Shur; Michael Friedman; R Guberman; michael sela
Local application of sustained-release delivery system of chlorhexidine in Down's syndrome population.
Clinical preventive dentistry 1991;13(5):9-14.
1991: Ziv Mazor; L Brayer; Michael Friedman; Doron Steinberg
Topical varnish containing strontium in a sustained-release device as treatment for dentin hypersensitivity.
Clinical preventive dentistry 1991;13(3):21-5.
1991: Doron Steinberg; U Amit; L Brayer; michael sela; Michael Friedman
The effect of sustained-release varnish of chlorhexidine in dental plastic shells on salivary Streptococcus mutans.
Clinical preventive dentistry 1991;13(2):9-12.
1991: Michael Friedman; Doron Steinberg; michael sela; A Soskolne
Structural and microbiological evaluation of a degradable sustained-release device for use in periodontal therapy.
Drug design and delivery 1991;7(3):241-50.
1990: Z Hussein; Michael Friedman
Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
Pharmaceutical research 1990;7(11):1167-71.
1990: K Egbaria; Michael Friedman
Sustained in vitro activity of human albumin microspheres containing chlorhexidine dihydrochloride against bacteria from cultures of organisms that cause urinary tract infections.
Antimicrobial agents and chemotherapy 1990;34(11):2118-21.
1990: Doron Steinberg; Michael Friedman; A Soskolne; michael sela
A new degradable controlled release device for treatment of periodontal disease: in vitro release study.
Journal of periodontology 1990;61(7):393-8.
1990: Michael Friedman; D Steinberg
Sustained-release delivery systems for treatment of dental diseases.
Pharmaceutical research 1990;7(4):313-7.
1990: Daniel Ziskind; Doron Steinberg; Ayala Stabholz; Michael Friedman; michael sela
The effect of sustained release application of chlorhexidine on salivary levels of Streptococcus mutans in partial denture wearers.
Journal of oral rehabilitation 1990;17(1):61-6.
1987: Z Hussein; Meir Bialer; Michael Friedman; I Raz
Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.
Biopharmaceutics & drug disposition 1987;8(5):427-35.